PaperSuppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy
References (30)
- et al.
High-affinity anti-oestrogen binding site distinct from the oestrogen receptor
Nature
(1980) - et al.
Induction of transforming growth factor betal in human breast cancer cells in vivo following tamoxifen treatment
Cancer Res
(1992) - et al.
Hormonal regulation of insulin-like growth factor gene expression in pig uterus
Endocrinology
(1990) - et al.
Role of insulin-like growth factors and the type I insulin-like factor receptor in the estrogen-stimulated proliferation of human breast cancer cells
J Biol Chem
(1990) - et al.
Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast
CRC Critical Rev Clin Lab Sci
(1988) - et al.
Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial
Breast Cancer Res Treat
(1986) - et al.
Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Breast and Bowel Project trial
J Clin Oncol
(1986) - et al.
Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer
J Clin Oncol
(1986) - et al.
Response to second-line hormone treatment for advanced breast cancer. Predictive value of ploidy determination
Cancer
(1990) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy
Lancet
(1992)Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy
Lancet
(1992)
Inhibition of protein kinase C by tamoxifen
Cancer Res
(1985)
Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase
Biochem Biophys Res Commun
(1984)
In vitro stimulation of human NK activity by an oestrogen antagonist (tamoxifen)
Eur J Cancer Clin Oncol
(1984)
Therapeutic implications of recent growth factor research
Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture
Cancer Res
(1984)
Cited by (49)
Circadian aspects of growth hormoneinsulin-like growth factor axis function in patients with lung cancer
2012, Clinical Lung CancerCitation Excerpt :IGFs have properties of tissue growth factors but also have additional well-recognized functions as hormones that regulate growth and energy metabolism at the whole organism level.39 IGF1 type I receptor (IGFIR) is commonly expressed by neoplastic cell lines and human cancers, and many cancer cell lines are mitogenically responsive to physiologic concentrations of IGF1.40-44 Although the bulk of circulating IGF1 and IGF2 is produced in the liver, these peptides are frequently expressed in neoplastic tissue, so they might influence cancers through autocrine, paracrine, or endocrine mechanisms.
An experimental model of diabetes and cancer in rats
1998, European Journal of CancerA Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer
2021, Clinical Cancer ResearchSimplifying the energy balance message for breast cancer prevention
2012, Cancer Prevention Research
Copyright © 1993 Published by Elsevier Ltd.